SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr Reddys Lab surges on reporting 7% rise in Q1FY14 consolidated net profit

31 Jul 2013 Evaluate

Dr Reddys Laboratories is currently trading at Rs 2216.00, up by 36.60 points or 1.68% from its previous closing of Rs 2179.40 on the BSE.

The scrip opened at Rs 2174.00 and has touched a high and low of Rs 2217.35 and Rs 2136.35 respectively. So far 15417 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 5 has touched a 52 week high of Rs 2400.75 on 15-Jul-2013 and a 52 week low of Rs 1603.00 on 31-Jul-2012.

Last one week high and low of the scrip stood at Rs 2393.30 and Rs 2136.00 respectively. The current market cap of the company is Rs 37064.73 crore.

The promoters holding in the company stood at 25.53% while Institutions and Non-Institutions held 41.53% and 15.79% respectively.

Dr Reddys Laboratories has reported results for the quarter ended June 30, 2013.

The company’s net profit declined by 63.49% at Rs 64.86 crore for the quarter as compared to Rs 177.66 crore for the same quarter in the previous year. Total income of the company has increased by 1.09% at Rs 1854.93 crore for quarter under review as compared to Rs 1834.94 crore for the quarter ended June 30, 2012.

On consolidated basis, the Group’s net profit after taxes rose by 7.45% at Rs 360.93 crore for the quarter under review as compared to Rs 335.98 crore for the June quarter of the previous year. Its total income has increased by 12.49% to Rs 2882.48 crore in Q1FY14 against Rs 2562.46 crore in Q1FY13.

Dr. Reddys Lab Share Price

1284.60 -8.65 (-0.67%)
11-May-2026 10:54 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1874.75
Dr. Reddys Lab 1284.60
Cipla 1334.95
Zydus Lifesciences 939.95
Lupin 2253.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×